A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms ACHIEVE I
  • Sponsors Allergan
  • Most Recent Events

    • 20 Apr 2018 According to an Allergan media release, data from this trial will be presented at the 70th Annual American Academy of Neurology (AAN) Meeting 2018.
    • 06 Feb 2018 According to an Allergan media release, additional results from this study are anticipated to be released at upcoming scientific meetings throughout 2018.
    • 06 Feb 2018 Results presented in an Allergan Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top